Medical Condition

nasopharyngeal carcinoma

Total Trials

16

Recruiting Now

16

Trial Phases

Phase 2, EARLY_Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for nasopharyngeal carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — nasopharyngeal carcinoma Clinical Trials

How many clinical trials are currently recruiting for nasopharyngeal carcinoma?

ClinicalMetric currently tracks 16 actively recruiting clinical trials for nasopharyngeal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nasopharyngeal carcinoma?

nasopharyngeal carcinoma research spans Phase 1 (1 trial), Phase 2 (6 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nasopharyngeal carcinoma clinical trial?

Eligibility criteria for nasopharyngeal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Sun Yat-sen University 6 trials

Jiangxi Provincial Cancer Hospital 2 trials

Zhongshan People's Hospital, Guangdong, China 1 trial

Fudan University 1 trial

Chongqing University Cancer Hospital 1 trial

nasopharyngeal carcinoma

Frequently Asked Questions — nasopharyngeal carcinoma Clinical Trials

Recruiting Clinical Trials

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Adebrelimab and Chemoradiotherapy in High-risk LANPC

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Screening for Early Diagnosis of Nose Cancer

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC